Amylyx Pharmaceuticals, Inc./$AMLX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
Ticker
$AMLX
Sector
Primary listing
Employees
123
Headquarters
Website
AMLX Metrics
BasicAdvanced
$1.3B
-
-$1.77
-
-
Price and volume
Market cap
$1.3B
52-week high
$16.96
52-week low
$2.60
Average daily volume
1.8M
Financial strength
Current ratio
14.244
Quick ratio
13.87
Profitability
EBITDA (TTM)
-192.96
Gross margin (TTM)
15,751.73%
Net profit margin (TTM)
22,448.42%
Operating margin (TTM)
29,104.21%
Effective tax rate (TTM)
0.42%
Revenue per employee (TTM)
-$10,000
Management effectiveness
Return on assets (TTM)
-39.44%
Return on equity (TTM)
-56.52%
Valuation
Price to revenue (TTM)
-1,559.017
Price to book
3.46
Price to tangible book (TTM)
3.46
Growth
Revenue change (TTM)
-100.34%
Earnings per share change (TTM)
-53.64%
3-year revenue growth (CAGR)
24.45%
3-year earnings per share growth (CAGR)
-24.97%
Bulls say / Bears say
Amylyx stopped developing AMX0035 for progressive supranuclear palsy after the drug did not outperform placebo in a mid-stage trial, ending both the study and its open-label extension and dropping plans for a late-stage PSP trial (Reuters).
The failure of the PSP trial caused AMLX shares to fall 1.7% in premarket trading, highlighting investor disappointment (Reuters).
AMX0035’s program has experienced repeated late-stage failures, including last year’s voluntary withdrawal of Relyvrio/Albrioza from the U.S. and Canada after an unsuccessful late-stage ALS trial, raising doubts about the drug’s commercial potential (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 8 Nov 2025.
AMLX News
AllArticlesVideos
Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results
Business Wire4 days ago
Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Business Wire2 weeks ago
Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amylyx Pharmaceuticals, Inc. stock?
Amylyx Pharmaceuticals, Inc. (AMLX) has a market cap of $1.3B as of November 10, 2025.
What is the P/E ratio for Amylyx Pharmaceuticals, Inc. stock?
The price to earnings (P/E) ratio for Amylyx Pharmaceuticals, Inc. (AMLX) stock is 0 as of November 10, 2025.
Does Amylyx Pharmaceuticals, Inc. stock pay dividends?
No, Amylyx Pharmaceuticals, Inc. (AMLX) stock does not pay dividends to its shareholders as of November 10, 2025.
When is the next Amylyx Pharmaceuticals, Inc. dividend payment date?
Amylyx Pharmaceuticals, Inc. (AMLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Amylyx Pharmaceuticals, Inc.?
Amylyx Pharmaceuticals, Inc. (AMLX) does not currently have a Beta indicator.